First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.
Atropos Health Raises $33M to Scale the Automation of High-Quality, Personalized Real-World Evidence Leveraging Generative AI tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.